AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03013998
Drug: Azacitidine (BAML-16-001-S12 Arm A)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 28-day cycle for up to 2 cycles or until unacceptable toxicity or death.
Trial: NCT03013998
Drug: Venetoclax (BAML-16-001-S12 Arm B)
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg, oral, on days 1 through 14 of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death. For Cycle 1, day 1 dose is 100 mg, day 2 dose 200 mg, and day 3 onward dose is 400 mg. (Dose adjusted by anti-fungal agent use per the package insert.)
Trial: NCT00556088
Drug: LBH589, Paclitaxel, Carboplatin, Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.~Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer.
Trial: NCT00477542
Drug: clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cohort- n- Clofarabine (mg/m2/day)~-1 3-10 20~1. 3-6 30~2. 3-6 40~3. 3-6 50~4. 3-6 60~5. 6-10 70
Trial: NCT01467531
Drug: Dolutegravir
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50mg q 24h
Trial: NCT01467531
Drug: Rlipivirine
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25mg q24h
Trial: NCT03013998
Drug: Azacitidine (BAML-16-001-S12 Arm B)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 75 mg/m2, IV or SC, on days 1-7 or days 1-5 and 8 and 9 or days 1-2 and 5-9 (based on institutional guidelines) of each 14-day cycle for up to 2 cycles or until unacceptable toxicity or death.
Trial: NCT03013998
Drug: ZE46-0134 (BAML-16-001-S21)
RxNorm normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg or 50 mg oral on Days 1-28 of each 28-day cycle for up to 24 cycles. On the first day of Cycle 1, a loading dose of 30 mg to 150 mg will be administered, after which the daily maintenance dose of 10 mg to 100 mg will be administered on days 2-28 of Cycle 1. Maintenance dose continues in subsequence cycles, for up to 24 cycles total.
Trial: NCT04409262
Drug: Remdesivir
RxNorm normalized name: remdesivir
DrugBank: Remdesivir (DB14761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive intravenous (IV) RDV
Trial: NCT04409262
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive IV TCZ
Trial: NCT02500732
Drug: Atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg PO the night before and the morning of the study tilt table test.
Trial: NCT02491632
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO
Trial: NCT00516945
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00281736
Drug: HPPH
RxNorm normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03546686
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembro will be administered 1-20 days before the cryoablation date per SOC and q3 weeks after surgery for 9 cycles per SOC.
Trial: NCT03546686
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 1mg/Kg IV is administered 1-5 days prior to cryoablation.
Trial: NCT03546686
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nivolumab 240mg IV flat dose is administered 1-5 days prior to cryoablation and 240mg IV every 2 weeks ± 3 days starting 3 (+/-1) weeks after surgery.
Trial: NCT02386475
Drug: citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
Trial: NCT02855125
Drug: TAS-114
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAS-114 was a modulator of 5-fluorouracil (5-FU).
Trial: NCT04236986
Drug: Lipopolysaccharide
RxNorm normalized name: Lipopolysaccharide
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS will be administered intravenously (1.0ng/kg; IV)
Trial: NCT02855125
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
Trial: NCT03820388
Drug: Propofol 2mg/kg
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg/kg
Trial: NCT03820388
Drug: Etomidate 0.3 mg/kg
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg
Trial: NCT03820388
Drug: Propofol 1 mg/kg
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 mg/kg Propofol
Trial: NCT03820388
Drug: Etomidate 0.15 mg/kg
DrugBank: Etomidate (DB00292)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg Etomidate
Trial: NCT02604134
Drug: Fluoride varnish
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
Trial: NCT02604134
Drug: Silver Nitrate
RxNorm normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
Trial: NCT00038571
Drug: PS341 (Bortezomib)
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
Trial: NCT03472885
Drug: Danicopan
RxNorm normalized name: Danicopan
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a daily oral dose of danicopan TID during the treatment period.
Trial: NCT01294319
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01294319
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03472885
Drug: Eculizumab
RxNorm normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants received intravenous eculizumab administered at the participant's usual dose and schedule.
Trial: NCT01160029
Drug: Nateglinide
RxNorm normalized name: Nateglinide
DrugBank: Nateglinide (DB00731)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nateglinide Tablets 120 mg
Trial: NCT00948896
Drug: trimethoprim-sulfamethoxazole (TS; TMP/SMX)
RxNorm normalized name: sulfamethoxazole / trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
Trial: NCT00948896
Drug: sulfadoxine-pyrimethamine (SP)
RxNorm normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: monthly dosing given as a single dose, 500mg/25mg tabs
Trial: NCT00948896
Drug: dihydroartemisinin-piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
Trial: NCT03601611
Drug: Tocilizumab (RoACTEMRA®)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prednisolon will be given in case of worsening of symptoms
Trial: NCT03448458
Drug: Gallium Ga 68-DOTATATE
RxNorm normalized name: Gallium (Ga 68) dotatate
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00943566
Drug: Sustained Release Morphine Sulfate
RxNorm normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
Trial: NCT01283061
Drug: Zafirlukast
RxNorm normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zafirlukast tablets 20 mg
Trial: NCT04501874
Drug: EMB-001
RxNorm normalized name: EMB
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 720 mg metyrapone/24 mg oxazepam mg BID
Trial: NCT01965600
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 125 mg, TID, 3 days, 1 of 2 periods
Trial: NCT01965600
Drug: PF-06282999
RxNorm normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, 500 mg, BID, 3 days, 1 of 2 periods
Trial: NCT00363272
Drug: ispinesib
RxNorm normalized name: Ispinesib
DrugBank: Ispinesib (DB06188)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04139057
Drug: EBV-specific TCR-T cell with anti-PD1 auto-secreted element
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were pre-conditioned with chemotherapy and infused with EBV-specific TCR-T cells with anti-PD1 auto-secreted element
Trial: NCT01156636
Drug: Sildenafil
RxNorm normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg 3 times/day for 1 year
Trial: NCT00387621
Drug: Nesiritide
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
Trial: NCT00387621
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
Trial: NCT04516616
Drug: Cisplatin+Albumin-bound paclitaxel (1 cycle) and PD-1 monoclonal antibody+Cisplatin+Albumin-bound paclitaxel (2 cycles)
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PD-1 monoclonal antibody （SHR-1210)：200mg，IV infusion，Q3W Cisplatin：75-80 mg/m2, IV infusion, Q3W Albumin-bound paclitaxel: 260 mg/m2，30min，IV infusion, Q3W
Trial: NCT02924311
Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
Trial: NCT00208858
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04046029
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin will be given as a bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg/h during the PCI procedure and for at least 30 minutes but no more than 4 hours afterwards. Following this mandatory infusion,a reduced-dose infusion (0.2 mg/kg/h) for up to 20 hours could be administered at physician discretion. An additional bivalirudin bolus of 0.3 mg/kg was given if the activated clotting time 5 minutes after the initial bolus was less than 225 seconds.
Trial: NCT01666301
Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00412555
Drug: oseltamivir [Tamiflu]
DrugBank: Oseltamivir acid (DB02600)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-75mg po daily for 6 weeks
Trial: NCT02451137
Drug: Insulin glargine, 300 U/ml
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT02451137
Drug: Insulin glargine, 100 U/ml
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT02451137
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT01034345
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
Trial: NCT00000291
Drug: Labetalol
RxNorm normalized name: Labetalol
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01977573
Drug: rhEPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
Trial: NCT03196401
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
Trial: NCT00781001
Drug: Cannabis
RxNorm normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
Trial: NCT06601205
Drug: Flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet daily until the day before surgery
Trial: NCT06601205
Drug: Finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 tablet daily until the day before surgery
Trial: NCT03576807
Drug: CD20 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total of 1 - 20×10\^6 CD20 CAR-T cells/kg will be administered by IV infusions.
Trial: NCT04300556
Drug: Farletuzumab ecteribulin
RxNorm normalized name: Farletuzumab ecteribulin
DrugBank: Farletuzumab ecteribulin (DB18857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Farletuzumab ecteribulin intravenous infusion.
Trial: NCT04300556
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone administered orally.
Trial: NCT04300556
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administered orally.
Trial: NCT02980211
Drug: Alveolar Ridge Reconstruction
RxNorm normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstruction of dehiscence defects in extraction sockets with a minimally invasive technique using a particulate bone allograft and a non-absorbable dense polytetrafluoroethylene (dPTFE) membrane
Trial: NCT01200251
Drug: Bimatoprost eyelash gel
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
Trial: NCT00978705
Drug: Autologous cultured keratinocyte cell
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x10\^7 cell/ vial
Trial: NCT00211198
Drug: ONTAK (denileukin difitox, DAB389IL-2)
RxNorm normalized name: denileukin diftitox Injection [Ontak]
DrugBank: Denileukin diftitox (DB00004)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04489511
Drug: STG-001
RxNorm normalized name: STG-001
DrugBank: STG-001 (DB16734)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1 or Dose 2 of STG-001 will be administered daily for 28 days to compare safety, pharmacokinetics and pharmacodynamics in Stargardt disease subjects.
Trial: NCT04392531
Drug: Cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the experimental group, cyclosporine will be started according to patient weight, and then increased depending on patient tolerance (monitoring renal function and blood pressure)
Trial: NCT00184730
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02885506
Drug: Oral administration of P218 capsules
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
Trial: NCT01041027
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01041027
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03648021
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: \>50kg: Paracetamol 1 gramme in a solution of 10mg/mL administred intravenously. 1 dose~\>50kg: Paracetamol 15mg/kg/dose in a solution 10mg/mL administred intravenously. 1 dose
Trial: NCT00001426
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00001426
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001426
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00042575
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00977600
Drug: Ammonul
RxNorm normalized name: Ammonul
DrugBank: Benzoic acid (DB03793)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00977600
Drug: Buphenyl
RxNorm normalized name: Buphenyl
DrugBank: Phenylbutyric acid (DB06819)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02335359
Drug: tranexamic acid diluted in 100 ml of saline solution (loading dose)
RxNorm normalized name: tranexamic acid 100 MG/ML
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02335359
Drug: tranexamic acid undiluted (continous infusion)
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03397966
Drug: recombinant human BNP(1-32)
RxNorm normalized name: BNP-32
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will receive an IV infusion of recombinant human BNP(1-32) for 240 minutes at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
Trial: NCT03397966
Drug: placebo (control, normal saline)
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive an IV infusion of placebo (normal saline) at a rate of 10 ng/kg/minute for 240 minutes, preceded by an IV bolus of 100 ng/kg.
Trial: NCT01519700
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients will be teated with Filgrastim
Trial: NCT03606473
Drug: d-amphetamine
RxNorm normalized name: d-amphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: is used to stimulate dopamine release in the brain
Trial: NCT00821600
Drug: risperidone IR and LAI formulation
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection